Payment overview · 2025
General Payments
$634.14
22 reported records · 7 companies
Healthcare provider profile · identity verified
Michael Brian Maris, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology · DENVER, CO · NPI 1053395624
Verified facts
What the public records show
CMS Open Payments records show Michael Brian Maris, MD received $634.14 in general payments during 2025 across 22 reported records.
ABBVIE INC. accounted for 47.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Xospata.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Cresemba as an associated drug or biological on 2800 records involving 1563 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Cresemba by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Xospata as an associated drug or biological on 1329 records involving 827 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Xospata by this doctor in 2024.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 25 records involving 24 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $302.36 | 47.7% | 13 | 2025 |
| Mesoblast, Inc. | Unresolved — no canonical attribution shown | $203.88 | 32.1% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $40.60 | 6.4% | 2 | 2025 |
| Autolus Inc | Unresolved — no canonical attribution shown | $29.42 | 4.6% | 1 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $22.24 | 3.5% | 1 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $18.40 | 2.9% | 1 | 2025 |
| Kite Pharma, Inc. | Unresolved — no canonical attribution shown | $17.24 | 2.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $634.14 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EPKINLY Normalized: epkinly |
Drug | ABBVIE INC. | $230.13 | 9 | 2025 |
Source payment records
|
|||||
| Ryoncil Normalized: ryoncil |
Drug | Mesoblast, Inc. | $203.88 | 3 | 2025 |
Source payment records
|
|||||
| IMBRUVICA Normalized: imbruvica |
Drug | ABBVIE INC. | $139.47 | 6 | 2025 |
Source payment records
|
|||||
| VENCLEXTA Normalized: venclexta |
Drug | ABBVIE INC. | $44.13 | 3 | 2025 |
Source payment records
|
|||||
| Xospata Normalized: xospata |
Drug | Astellas Pharma US Inc | $40.60 | 2 | 2025 |
Source payment records
|
|||||
| REBLOZYL Normalized: reblozyl |
Biological | Celgene Corporation | $22.24 | 1 | 2025 |
Source payment records
|
|||||
| Vanflyta Normalized: vanflyta |
Drug | Daiichi Sankyo Inc. | $18.40 | 1 | 2025 |
Source payment records
|
|||||
| Yescarta Normalized: yescarta |
Drug | Kite Pharma, Inc. | $17.24 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Xospata xospata |
2025 | Xospata | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Cresemba open payments reported associated product |
CMS Open Payments — General Payments 2800 supporting records · 1563 recipient NPIs · example record 1238560682 |
Cresemba · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Xospata open payments reported associated product |
CMS Open Payments — General Payments 1329 supporting records · 827 recipient NPIs · example record 1238560680 |
Xospata · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 25 supporting records · 24 recipient NPIs · example record 1184385048 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Acyclovir | Acyclovir | 91 | 24 |
| Jakafi | Ruxolitinib Phosphate | 78 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 70 | 19 |
| Valacyclovir | Valacyclovir Hcl | 63 | 18 |
| Pantoprazole Sodium | Pantoprazole Sodium | 38 | suppressed |
| Ursodiol | Ursodiol | 35 | suppressed |
| Prevymis | Letermovir | 34 | suppressed |
| Gabapentin | Gabapentin | 31 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 29 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 28 | suppressed |
| Potassium Chloride | Potassium Chloride | 23 | suppressed |
| Eliquis | Apixaban | 21 | suppressed |
| Prednisone | Prednisone | 21 | suppressed |
| Posaconazole | Posaconazole | 20 | suppressed |
| Omeprazole | Omeprazole | 17 | suppressed |
| Tacrolimus | Tacrolimus | 17 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 17 | suppressed |
| Cresemba | Isavuconazonium Sulfate | 15 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 15 | suppressed |
| Levofloxacin | Levofloxacin | 15 | suppressed |
| Allopurinol | Allopurinol | 14 | suppressed |
| Xospata | Gilteritinib Fumarate | 14 | suppressed |
| Dexamethasone | Dexamethasone | 13 | suppressed |
| Idhifa | Enasidenib Mesylate | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Revlimid | Lenalidomide | 13 | suppressed |
| Brukinsa | Zanubrutinib | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Imatinib Mesylate | Imatinib Mesylate | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 11 | suppressed |
| Promacta | Eltrombopag Olamine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $634.14 · 22 records | ABBVIE INC. | EPKINLY, IMBRUVICA, REBLOZYL, Ryoncil, VENCLEXTA, Vanflyta, Xospata, Yescarta | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Xospata play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error